Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection

AIDS

Volumn 20, Issue 14, 2006, Pages 1795-1804

  Vieillard, Vincent ^a   Costagliola, Dominique ^b   Simon, Anne ^a   Debré, Patrice ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

CD4 T cells; gp41; HIV 1; NK lysis; NKp44L

Indexed keywords

GLYCOPROTEIN GP 41;

ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; CYTOMETRY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD4; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE PROGRESSION; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; INTERFERON TYPE II; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 33748501031     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000244198.65263.17     Document Type: Article

References (42)

1. + T-cell depletion in HIV disease. Nature 2001; 410:974-979.
2. + T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat Med 2002; 8:319-323.
3. + cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA 2005; 102:10981-10986.
4. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199-210.
5. Mascola JR. Defining the protective antibody response for HIV-1. Curr Mol Med 2003; 3:209-216.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
7. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888.
8. Hovanessian AG, Briand JP, Said EA, Svab J, Ferris S, Dali H, et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity 2004; 21:617-627.
9. Cardoso RM, Zwick MB, Stanfield RL, Kunnert R, Binley JM, Katinger H, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22:163-173.
10. Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002; 16:2019-2025.
11. McGaughey GB, Barbato G, Bianchi E, Freidinger RM, Garsky VM, Hurni WN, et al. Progress towards the development of a HIV-1 gp41-directed vaccine. Curr HIV Res 2004; 2:193-204.
12. Candotti D, Costagliola D, Joberty C, Bonduelle O, Rouzioux C, Autran B, et al. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. French ALT Study Group. J Med Virol 1999; 58:256-263.
13. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4R T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-525.
14. Le Dorfec E, Chevret S, Costagliola D. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treament difference measured on summary statistics. Stat Med 1999; 18:1803-1817.
15. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252-1261.
16. Learmont JC, Geczy AF, Mills J, Ashton LJ, Raynes-Greenow CH, Garsia RJ, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715-1722.
17. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997; 349:1219-1220.
18. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271:324-328.
19. Kaslow RA, Carrigton M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405-411.
20. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-2714.
21. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
22. + T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
23. Allain JP, Laurian Y, Paul DA, Verroust F, Leuther M, Gazengel C, et al. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med 1987; 317:1114-1121.
24. Hogervorst E, Jurrians S, de Wolf F, van Wijk A, Wiersma A, Valk M, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995; 171:811-821.
25. Lange JM, de Wolf F, Krone WJ, Danner SA, Coutinho RA, Goudsmit J. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1987; 1:155-159.
26. Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, et al.Correlationbetween humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 1998; 178:1306-1316.
27. Chien PC Jr, Cohen S, Kleeberger C, Giorgi J, Phair J, Zolla-Pazner S, et al. High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis 2002; 186:205-213.
28. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76:6780-6790.
29. Richman DD, Wrint T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100:4144-4149.
30. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
31. Trkola A, Kuster H, Leeman C, Oxenius A, Fagard C, Furrer H, et al. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-1792.
32. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
33. Lee SJ, Garza L, Yao J, Notkins AL, Zhou P. A nonneutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: a new way to fight HIV. J Immunol 2004; 173:4618-4626.
34. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339:383-385.
35. Gougeon ML. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003; 3:392-404.
36. Bizzini B, Volpato I, Lachgar A, Cohen P, Gringeri A. IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. Biomed Pharmacother 1999; 53:87-89.
37. Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000; 97:3515-3519.
38. Goedert JJ, Mendez H, Drummond JE, Robert-Guroff M, Minkoff HL, Holman S, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321:1141-1148.
39. Peretz Y, Alter G, Boisvert MP, Hatzakis G, Tsoukas CM, Bernard NF. Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J Virol 2005; 79:4908-4917.
40. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191:2053-2063.
41. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5:996-1002.
42. Vivier E, Malissen B. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol 2005; 6:17-21.